Research ExplorerPublicationsQuality of life in patients with relapsed/refractory multipl...

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

Standard

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. / Ludwig, Heinz; Pönisch, Wolfram; Knop, Stefan; Egle, Alexander; Hinke, Axel; Schreder, Martin; Lechner, Daniel; Hajek, Roman; Gunsilius, Eberhard; Petzer, Andreas; Weisel, Katja; Niederwieser, Dietger; Einsele, Hermann; Willenbacher, Wolfgang; Rumpold, Holger; Pour, Ludek; Jelinek, Tomas; Krenosz, Karl Jochen; Meckl, Angela; Nolte, Sandra; Melchardt, Thomas; Greil, Richard; Zojer, Niklas.

In: LEUKEMIA LYMPHOMA, Vol. 61, No. 2, 02.2020, p. 377-386.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ludwig, H, Pönisch, W, Knop, S, Egle, A, Hinke, A, Schreder, M, Lechner, D, Hajek, R, Gunsilius, E, Petzer, A, Weisel, K, Niederwieser, D, Einsele, H, Willenbacher, W, Rumpold, H, Pour, L, Jelinek, T, Krenosz, KJ, Meckl, A, Nolte, S, Melchardt, T, Greil, R & Zojer, N 2020, 'Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population', LEUKEMIA LYMPHOMA, vol. 61, no. 2, pp. 377-386. https://doi.org/10.1080/10428194.2019.1666381

APA

Ludwig, H., Pönisch, W., Knop, S., Egle, A., Hinke, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Rumpold, H., Pour, L., Jelinek, T., Krenosz, K. J., Meckl, A., ... Zojer, N. (2020). Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. LEUKEMIA LYMPHOMA, 61(2), 377-386. https://doi.org/10.1080/10428194.2019.1666381

Vancouver

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M et al. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. LEUKEMIA LYMPHOMA. 2020 Feb;61(2):377-386. https://doi.org/10.1080/10428194.2019.1666381

Bibtex

@article{a8e5c0243bff4e92b17f82dea5c270fd,
title = "Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population",
abstract = "This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.",
author = "Heinz Ludwig and Wolfram P{\"o}nisch and Stefan Knop and Alexander Egle and Axel Hinke and Martin Schreder and Daniel Lechner and Roman Hajek and Eberhard Gunsilius and Andreas Petzer and Katja Weisel and Dietger Niederwieser and Hermann Einsele and Wolfgang Willenbacher and Holger Rumpold and Ludek Pour and Tomas Jelinek and Krenosz, {Karl Jochen} and Angela Meckl and Sandra Nolte and Thomas Melchardt and Richard Greil and Niklas Zojer",
year = "2020",
month = feb,
doi = "10.1080/10428194.2019.1666381",
language = "English",
volume = "61",
pages = "377--386",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "2",

}

RIS

TY - JOUR

T1 - Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

AU - Ludwig, Heinz

AU - Pönisch, Wolfram

AU - Knop, Stefan

AU - Egle, Alexander

AU - Hinke, Axel

AU - Schreder, Martin

AU - Lechner, Daniel

AU - Hajek, Roman

AU - Gunsilius, Eberhard

AU - Petzer, Andreas

AU - Weisel, Katja

AU - Niederwieser, Dietger

AU - Einsele, Hermann

AU - Willenbacher, Wolfgang

AU - Rumpold, Holger

AU - Pour, Ludek

AU - Jelinek, Tomas

AU - Krenosz, Karl Jochen

AU - Meckl, Angela

AU - Nolte, Sandra

AU - Melchardt, Thomas

AU - Greil, Richard

AU - Zojer, Niklas

PY - 2020/2

Y1 - 2020/2

N2 - This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.

AB - This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.

U2 - 10.1080/10428194.2019.1666381

DO - 10.1080/10428194.2019.1666381

M3 - SCORING: Journal article

C2 - 31556753

VL - 61

SP - 377

EP - 386

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 2

ER -